Brett K. Haumann M.D., M.B.A. — Senior VP of Clinical Development & Chief Medical Officer at Theravance Biopharma

Dr. Brett K. Haumann, M.D., M.B.A. has been the Chief Medical Officer and Senior Vice President of Clinical Development at Theravance Biopharma, Inc. since March 1, 2016. Dr. Haumann served as Senior Vice President of Clinical Development and Operations at Theravance Biopharma, Inc. since December 2014. Dr. Haumann served as Vice President of Clinical Development at Theravance Inc. since October 2013. Dr. Haumann served as a Vice President Clinical Development and Operations at Theravance Biopharma, Inc. He served as Chief Medical Officer of Circassia Limited since September 2012 until July 3, 2013. Dr. Haumann has extensive experience of leading global phase III development programmes, managing interactions with regulatory agencies and scientific opinion leaders and co-ordinating market access and commercial activities. Dr. Haumann has over 15 years' experience of pharmaceutical development gained at Glaxo Wellcome and GlaxoSmithKline (GSK). He served as an Executive Director of Circassia Limited since September 2012 until July 3, 2013. During this time, he held a number of positions of increasing seniority and served as Vice President of Medicines Development Leader, where he led a multifunctional team developing GSK's next generation of inhaled respiratory products. Prior to his time in the pharmaceutical industry, Dr. Haumann practised internal medicine and conducted clinical research in South Africa. He gained his Medical Degree from the University of Witwatersrand, South Africa and also holds an MBA from the UK's Open University.